{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:19:20Z","timestamp":1791235160841,"version":"4.1.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Weifang Science and Technology Development Program","award":["2025YX098"],"award-info":[{"award-number":["2025YX098"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,12]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>Rituximab-associated interstitial lung disease (ILD) may initially be asymptomatic, and serial monitoring of serum tumor necrosis factor-alpha levels may facilitate timely diagnostic intervention with pulmonary computed tomography.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 73-year-old patient with diffuse large B-cell lymphoma (DLBCL) developed ILD during treatment with a rituximab-containing regimen.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnoses:<\/jats:title>\n                    <jats:p>Rituximab-associated interstitial disease was made.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>The patient was treated with corticosteroids, intravenous immunoglobulin, and antifibrotic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The ILD progressed, and the patient ultimately succumbed to type I respiratory failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>Clinicians should remain vigilant for rituximab-associated ILD, which, although uncommon, can progress rapidly and result in poor outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000046554","type":"journal-article","created":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:04:03Z","timestamp":1765814643000},"page":"e46554","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Fatal interstitial lung disease associated with rituximab in diffuse large B-cell lymphoma: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0592-3740","authenticated-orcid":false,"given":"Li","family":"Li","sequence":"first","affiliation":[{"name":"Department of Respirology, Yidu Central Hospital of Weifang, Qingzhou, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Respirology, Yidu Central Hospital of Weifang, Qingzhou, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Respirology, Yidu Central Hospital of Weifang, Qingzhou, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1607-9967","authenticated-orcid":false,"given":"Xiang-Lei","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Yidu Central Hospital of Weifang, Qingzhou, Shandong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20251215","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","article-title":"Non-infectious pulmonary toxicity of rituximab: a systematic review.","volume":"51","author":"Hadjinicolaou","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"R2-20251215","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s40261-024-01400-z","article-title":"Diagnosis and management of drug-induced interstitial lung disease in the context of anti-cancer therapy: a multidisciplinary viewpoint by Portuguese experts.","volume":"44","author":"Fontes E Sousa","year":"2024","journal-title":"Clin Drug Investig"},{"key":"R3-20251215","first-page":"693","article-title":"Expert consensus on the diagnosis and treatment of anticancer drug-induced interstitial lung disease [in Chinese].","volume":"44","year":"2022","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"R4-20251215","doi-asserted-by":"crossref","first-page":"e5797","DOI":"10.1002\/pds.5797","article-title":"Rising cases of drug-induced pulmonary fibrosis: analysis of the Food and Drug Administration Adverse Event Reporting System (FAERS) database, 2000\u20132022.","volume":"33","author":"McCall","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R5-20251215","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/sj.thj.6200133","article-title":"Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment.","volume":"2","author":"Bienvenu","year":"2001","journal-title":"Hematol J"},{"key":"R6-20251215","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3402\/ecrj.v2.27178","article-title":"Rituximab-induced interstitial lung disease: five case reports.","volume":"2","author":"Naqibullah","year":"2015","journal-title":"Eur Clin Respir J"},{"key":"R7-20251215","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/jcpt.12052","article-title":"Fatal interstitial lung disease induced by rituximab-containing chemotherapy, treatment with TNF-\u03b1 antagonist and cytokine profiling: a case-report and review of the literature.","volume":"38","author":"Wu","year":"2013","journal-title":"J Clin Pharm Ther"},{"key":"R8-20251215","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/jcpt.12198","article-title":"Involvement of NLRP3 inflammasome in rituximab-induced interstitial lung disease: a case report.","volume":"39","author":"Kong","year":"2014","journal-title":"J Clin Pharm Ther"},{"key":"R9-20251215","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1183\/09031936.00080209","article-title":"Rituximab-induced lung disease: a systematic literature review.","volume":"35","author":"Liote","year":"2010","journal-title":"Eur Respir J"},{"key":"R10-20251215","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1002\/art.38798","article-title":"Induction of interleukin-6 production by rituximab in human B cells.","volume":"66","author":"Jones","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"R11-20251215","doi-asserted-by":"crossref","first-page":"1002959","DOI":"10.3389\/fimmu.2022.1002959","article-title":"Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.","volume":"13","author":"Mu\u00f1iz","year":"2022","journal-title":"Front Immunol"},{"key":"R12-20251215","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1002\/ppul.20864","article-title":"Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.","volume":"44","author":"Bitzan","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"R13-20251215","doi-asserted-by":"crossref","first-page":"e6898","DOI":"10.1002\/cam4.6898","article-title":"Drug-induced pneumonitis risk in diffuse large B-cell\/follicular lymphoma patients treated with R-CHOP-like regimen is associated with the use of granulocyte colony-stimulating growth factors.","volume":"13","author":"Kaprio","year":"2024","journal-title":"Cancer Med"},{"key":"R14-20251215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0272-5231(03)00143-6","article-title":"Bronchoalveolar lavage in drug-induced lung disease.","volume":"25","author":"Costabel","year":"2004","journal-title":"Clin Chest Med"},{"key":"R15-20251215","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1002\/ajh.20910","article-title":"Rituximab-induced interstitial lung disease.","volume":"82","author":"Wagner","year":"2007","journal-title":"Am J Hematol"},{"key":"R17-20251215","first-page":"527","article-title":"Interstitial lung disease presents with varying characteristics in patients with non-Hodgkin lymphoma undergoing rituximab-containing therapies.","volume":"104","author":"Zou","year":"2025","journal-title":"Ann Hematol"},{"key":"R18-20251215","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/s12890-025-03802-x","article-title":"Rituximab induced lung injury.","volume":"25","author":"Chari","year":"2025","journal-title":"BMC Pulm Med"},{"key":"R19-20251215","doi-asserted-by":"crossref","first-page":"103668","DOI":"10.1016\/j.autrev.2024.103668","article-title":"Treatment of acute exacerbation in interstitial lung disease secondary to autoimmune rheumatic diseases: more questions than answers.","volume":"23","author":"Luppi","year":"2024","journal-title":"Autoimmun Rev"},{"key":"R20-20251215","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.","volume":"188","author":"Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"R21-20251215","first-page":"e2022038","article-title":"Intravenous immunoglobulin for acute exacerbation of fibrotic idiopathic interstitial pneumonias.","volume":"39","author":"Higo","year":"2022","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"R22-20251215","doi-asserted-by":"crossref","first-page":"12528","DOI":"10.1038\/s41598-023-39101-w","article-title":"Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world.","volume":"13","author":"Kato","year":"2023","journal-title":"Sci Rep"},{"key":"R23-20251215","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1136\/annrheumdis-2018-214263","article-title":"Association of MUC5B promoter polymorphism with interstitial lung disease in myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis.","volume":"78","author":"Namba","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"R24-20251215","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/jcm10071384","article-title":"Telomeres in interstitial lung disease.","volume":"10","author":"Stock","year":"2021","journal-title":"J Clin Med"},{"key":"R25-20251215","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s13023-024-03410-8","article-title":"Associations between genetic variants of Toll-interacting proteins and interstitial lung diseases: a systematic review and meta-analysis.","volume":"19","author":"Li","year":"2024","journal-title":"Orphanet J Rare Dis"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046554","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T16:04:06Z","timestamp":1765814646000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000046554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":24,"journal-issue":{"issue":"50","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000046554","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2025-07-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}